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Primary membranous nephropathy (MN) is a frequent cause of NS in adults. In native
kidneys the disease may progress to ESRD in the long term, in some 40–50%
of untreated patients. The identification of the pathogenic role of anti-podocyte
autoantibodies and the development of new therapeutic options has achieved an
amelioration in the prognosis of this disease. MN may also develop in renal allograft
as a recurrent or a de novo disease. Since the de novo MN may have some different
pathogenetic and morphologic features compared to recurrent MN, in the present
paper we will deal only with the recurrent disease. The true incidence of the recurrent
form is difficult to assess. This is mainly due to the variable graft biopsy policies in
kidney transplantation, among the different transplant centers. Anti-phospholipase A2
receptor (PLA2R) autoantibodies are detected in 70–80% of patients. The knowledge
of anti-PLA2R status before transplant is useful in predicting the risk of recurrence. In
addition, the serial survey of the anti-PLA2R titers is important to assess the rate of
disease progression and the response to treatment. Currently, there are no established
guidelines for prevention and treatment of recurrent MN. Symptomatic therapy may help
to reduce the signs and symptoms related to the nephrotic syndrome. Anecdotal cases of
response to cyclical therapy with steroids and cyclophosphamide have been published.
Promising results have been reported with rituximab in both prophylaxis and treatment
of recurrence. However, these results are based on observational data, and prospective
controlled trials are still missing.
Keywords: membranous nephropathy, recurrent membranous nephropathy, kidney transplant, proteinuria, anti-
PLA2R antibodies, rituximab, prognosis
INTRODUCTION
Membranous nephropathy (MN) is a podocytopathy histologically characterized by uniform
thickening of the glomerular basement membrane due to the presence of sub-epithelial immune
deposits. It can be secondary to a variety of causes, such as infections, autoimmune diseases, solid
tumors, and medical reactions (1, 2) but in most cases (about 75%) it is an autoimmune kidney-
specific disease defined as primary MN, that will be, together with its recurrence after kidney
transplantation, the topic of this review.
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Primary MN is one of the most common causes of nephrotic
syndrome (NS) in adults and may lead to end-stage renal disease
(ESRD) in the long term in some 40–50% of untreated patients
(3–5), for whom kidney transplantation is the treatment of
choice. However, after transplantation primary MNmay develop
again, either as a recurrence of the original disease or as a de
novo form. When MN develops after renal transplantation, it
negatively impacts on graft survival. Thus, the knowledge of the
factors related with its recurrence and progression in the graft has
important clinical implications.
Here we review the diagnostic approach, preventive measures
and treatment strategies available for patients with recurrentMN.
PRIMARY MN
The natural history of primary MN follows three major clinical
courses: spontaneous remission, persistent proteinuria and slow
progression to ESRD; those patients with severe and un-remitting
NS may also suffer from disabling and even life-threatening
extra-renal complications, such as thrombo-embolic events and
cardiovascular disease (6, 7).
Our understanding of the pathogenesis of primary MN has
greatly improved in the past 10 years. In 2009, Beck et al.
identified in the M-type phospholipase A2 receptor (PLA2R),
a 185 kDa type I transmembrane glycoprotein expressed
on glomerular podocytes, the major target antigens of the
autoantibodies involved in primary MN. Circulating IgG4 anti-
PLA2R antibodies are detectable in 70% of patients with active
primary MN, and PLA2R staining colocalized with IgG4 in
glomerular subepithelial deposits (8–13). A recent meta-analysis
of 35 studies involving about 6,000 patients investigated the
diagnostic test accuracy of serum anti-PLA2R antibodies and
glomerular PLA2R antigen in discriminating between primary
and non-primary MN. The overall sensitivity and specificity for
serum anti-PLA2R antibodies was 65 and 97%, respectively and
those for glomerular PLA2R antigen of 79 and 90%, respectively.
The relatively low sensitivity of the serological test might suggest
limitations in the presence of a negative result which should
then require the need for a renal biopsy and for further research
to establish potential secondary causes of MN. However, both
serological and histological tests have high specificity, which
means that a positive result indicates a highly likely diagnosis
of primary MN. Besides a diagnostic role, in patients with
primaryMN, anti-PLA2R autoantibodies levels correlate with the
immunological activity of the disease and provide information
about its severity, long term outcome and treatment response
(14, 15). This prognostic behavior of anti-PLA2R antibodies
emphasizes their etiological role in primary MN, instead of
simply being a biomarker of the disease (11, 16, 17).
In about 5% of cases of primary MN without anti-PLA2R,
anti-thrombospondin type 1 domain-containing 7A (THSD7A)
antibodies can be detected (18–20). In these patients a higher
incidence of neoplasias has been reported, but the precise role
of this antigen in this clinical context is currently a matter of
investigation (21). No autoantibodies have yet been identified in
the remaining primary MN patients (15–20%).
A genetic contribution to the development of primary MN
is now well-established. A series of three independent genoma-
wide association study in biopsy-proven cases of primary MN
all of white ethnicity, showed that HLA-DQA1 and PLA2R1
haplotypes were associated with primary MN with high levels of
statistical significance, with a combined odds ratio of about 80 for
individuals homozygous for both risk alleles (22–25).
In patients with primary MN immunosuppression is reserved
to those with severe unremitting NS, usually after at least
6 months of surveillance with symptomatic treatment (26).
Traditional immunosuppressive regimens have included cyclical
therapy with steroids alternated with an alkylating agent
(cholambucil or cyclophosphamide) for 6 months, calcineurin
inhibitors for 6 or more months, and more recently a
B cell-targeted therapy with rituximab. Since patients with
immunologically active disease can now be separated from
those with inactive form, therapeutic initiatives can be tailored
depending on the presence and levels of pathogenic antibodies,
rather than empirically based on the clinical consequences of the
glomerular immune damage such as proteinuria or reduced GFR.
Serial changes in anti-PLA2R levels during treatment herald a
response when falling titers indicate the immunologic remission
of the disease.
RECURRENT MN
Like other autoimmune diseases, MN may recur after
transplantation, leading to proteinuria and increasing risk
of graft failure (27–31). The rate of recurrence may range
between 30 and 45%, with higher rates reported by centres
performing protocol biopsies (32, 33).
RISK FACTORS FOR RECURRENCE
An early detection of patients whomay develop recurrence would
be helpful; unfortunately no baseline clinical characteristics have
been reported to predict recurrence so far.
The genetic predisposition to the disease, due to the
interaction of pathological HLA class II alleles with some
PLA2R gene variants, has not been replicated in the post-
transplant setting.
Some old studies suggested that MN would be more likely to
recur in living than in deceased donor transplantations, assuming
a relationship between genetic factors and MN susceptibility
(34, 35). For example, Andrésdóttir et al. reported a cumulative
rate of post-transplant disease recurrence of 70% in living
related and of 21% in living unrelated donor transplants
(36). In contrast, in the combined Lyon-Louvain Medical
School series, recurrence was equally frequent in recipients of
deceased and living donor transplant (37), and Dabade et al.
described a higher number of recurrences among recipients
of deceased donor kidneys (29). Referring to the European
Renal Association-European Dialysis and Transplant Association
(ERA-DTA) database, Pippias et al. showed by multivariate
analysis that in transplanted patients with underlying primary
MN, the 5- and 10-year death-adjusted graft survival was
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significantly better in living related donor transplants compared
with deceased donors (38); their conclusions were against the
reluctance to use living transplant donors in MN as well in other
primary glomerulonephritis.
ANTI-PLA2R ANTIBODIES IN RECURRENT
MN
The identification of the main target antigen in primary MN, has
focused the attention to the role played by aPL2R autoantibodies
in the recurrence of the disease in kidney transplant.
There is now evidence that recurrent MN is triggered by
the binding of recipient autoantibodies to the target antigen
expressed on podocytes in the donor kidney. Stahl et al. first
reported a case of recurrent MN with high titers of anti-PLA2R
antibodies at the time of transplant and at recurrence (16). Since
then, the relevance of monitoring anti-PLA2R activity to assess
the risk of recurrence of primaryMNhas been extensively studied
(see Table 1).
The percentage of transplant candidates with primary MN
who have circulating anti-PLA2R antibodies is the same as in
the general primary MN population (70–80%) (39, 42, 43).
These patients have a 60–76% risk of hystological recurrence,
vs. a significantly lower risk in antibody negative patients (28–
30%) (17, 39, 40, 42). Kattah et al. reported that among 26
transplanted patients with underlying primaryMN, 18 developed
recurrent MN and 8 did not. In the recurrent group, 10 out
of 17 were anti-PLA2R positive at the time of transplantation
(55%), as well as 2/7 in the non-recurrent group (25%). In their
cohort, the positive predictive value (PPV) of pretransplant anti-
PLA2R antibodies for recurrent MN was 83% and the negative
predictive value (NPV) was 42%, thus, in their study, 58% of
seronegative patients at transplantationmay also have recurrence
(39). Quintana et al. studied 21 Spanish patients with primary
MN before transplantation. The recurrence of the disease was
significantly correlated with a positive ELISA assay at graft biopsy
(P = 0.017) or anti-PLA2R seropositivity before transplantation
(P = 0.03). In order to better define the pretransplant anti-
PLA2R cut-off level that could more accurately predict rMN, the
Authors performed a receiver operating characteristic analysis
(ROC), and found that an anti-PLA2R cut-off of 45 RU/mL
pretransplantation, was predictive of primary MN recurrence
with a sensitivity of 85.3%, a specificity of 85.1%, a NPV of
92% and an area under the curve of 90.8 % (P = 0.03) (40).
Likewise, Gupta et al. showed that 5 out of 6 transplanted
patients (83%) with a biopsy-proven diagnosis of recurrent
MN, were anti-PLA2R positive pretransplant, with a median
titer of 82 RU/mL vs. none of the 10 without anti-PLA2R
before surgery. Based upon their results, they found that an
ELISA titer above 30 RU/mL, provided a sensitivity of 83%,
a specificity of 100%, a PPV of 100% and a NPV of 91%
for recurrence. Pooling together these data with those from
Quintana et al. (n = 21), their ROC analysis showed that a
pretransplant anti-PLA2R cut-off titer above 29 RU/mL was
predictive of recurrence with a sensitivity of 85% and a specificity
of 92% (41). These quantitative results, which have never been
reported previously in a clinical cohort, may contribute to a better
identification of patients at risk of recurrence for prognostic and
therapeutic purposes.
The strong correlation between anti-PLA2R titer and the risk
of primary MN recurrence stressed by these studies was not
confirmed by others, which reported a significantly lower PPV
in seropositive patients (40 to 50%). A study by Debiec et al.
reported that anti-PLA2R antibodies were implicated in only 5 of
10 patients with recurrent MN; moreover, by studying the levels
of anti-PLA2R and the timing of the recurrence of the disease,
they showed a marked heterogeneity in the kinetics and titers
of anti-PLA2R, showing no simple association between anti-
PLA2R activity in transplantation and the risk of recurrence (11).
Similarly, Seitz-Polski et al. found that only a positive IgG4 anti-
PLA2R1 activity during the follow-up (more than month 6) was
significantly related to the recurrence (P = 0.0048): among 10
anti-PLA2R seropositive patients at transplantation, recurrence
occurred only in the four patients who maintained seropositivity
during their follow up (17).
Several biases in these studies may explain the opposing
results reported without lessening the predictive value of
anti-PLA2R for recurrence risk. The main one concerns
the wide variability of the therapeutical protocols applied.
A more intensive induction immunosuppression and the
modulation of the maintenance immunosuppressive therapy
could interfere with the autoantibody production and their
circulating post-transplant levels (39). Consequently recurrence
may be anticipated or delayed. This offers an explanation for the
contrasting results reported by Quintana et al. and Seitz-Polski
et al. who treated with the induction therapy 42 and 60% of their
patients, respectively. Another bias could be represented by the
lack of quantification of anti-PLA2R titer in some studies. This
may overestimate a very low titer, not reaching the cut-off level
predicting the recurrence. Finally, the use of renin-angiotensin
system blockers associated with calcineurin inhibitors could have
masked, in some studies, a subclinical recurrence with low
grade proteinuria.
In summary, the available studies suggest that the benefit of
anti-PLA2R antibodies titration lies in identification of recipients
at risk of recurrence and possibly achieving an early diagnosis
of recurrent MN. However, anti-PLA2R remains an imperfect
diagnostic tool because seropositivity does not necessarily
imply recurrence, as well as seronegativity does not necessarily
exclude it.
OUTCOME OF RECURRENT MN
Two peaks of MN recurrence have been described: an
“early recurrence” within the first 6–12 months after
transplantation, and a late-onset recurrence at about 5 years after
transplant (29, 42).
Early recurrence, most likely due to deposition of circulating
anti-PLA2R present at transplantation in the graft (32), is usually
detected by protocol biopsies in patients with absent or mild
clinical manifestation of the disease (28, 29). The histologic
features of early recurrence, that can be observed as early as
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TABLE 1 | PLA2R positivity and recurrent MN.
References N (%) recurrence
MN
PLA2R+
at Tx
PLA2R+
at recurrence
Median (range)
pre-Tx titer in rMN
PPV/NPV
(%)
COMMENT
Kattah et al. (39) 18/26 (69) 10/17 with recurrence
2/7 without recurrence
7/18 in post-Tx
period
19 (0–1,200)
Western blot
83/42
for pre-Tx
PLA2R
Quintana et al. (40) 7/21 (33) 6/7 with recurrence
5/14 without
recurrence
6/7 741 (11-1500)
ELISA
85/92 -Recurrence significantly associated with
high level PLA2R+ before Tx (P = 0.03)
-A cut–off level of 45 U/mL during pre-Tx
period predicted rMN with a sensitivity of
85%, specificity of 85% and a NPV of 92%
Gupta et al. (41) 6/16 (37) 5/6 with recurrence
0/10 without
recurrence
5/6 82 (31-1500)
ELISA
100/91 Combining data with those of Quintana
et al., Pre-Tx APLA2R >29 RU/mL
predicted rMN with a sensitivity of 85% and
a specificity of 92%
Debiec et al. (11) 10/10 (100) 4/4 with available
serum
5/10 NA NA
Seitz-Polski et al. (17) 5/13 (38) 4/5 with recurrence
6/8 without
recurred]nce
4/5 748 (137-3000) 40/80 Presence of PLA2R at the time of Tx does
not imply recurrence (P = 0.6). Positive
PLA2R activity during follow up(>6 months)
significantly correlates to recurrence
(P = 0.048)
PLA2R, anti-phospholipase A2 receptor; Tx, transplant; PPV, positive predictive value; NPV, negative predictive value; NA, not available.
1–2 weeks after surgery (40), are often different from those
observed in patients with clinically evident disease. For example,
light microscopy may not identify subepithelial deposits and
basement membrane spikes, and C3 staining appears to be
weak or absent at immunofluorescence (29). In contrast, at
electron microscopy extensive podocyte foot process fusions and
subepithelial electron dense deposits are seen. A fundamental
finding for diagnosis is the presence of PLA2R staining within
the glomerular immunodeposits (11, 44).
LateMN recurrence is clearly the result of new post-transplant
production of anti-PLA2R antibodies. It is usually diagnosed in
patients with a progressive increase in proteinuria evolving in
a full-blown NS. Histologically, the features of late recurrence
resemble those observed in the native kidney, and the glomerular
lesions can be associated with vascular and tubulo-interstitial
damage caused by rejection, CNI toxicity or infection.
It is clear that a protocol biopsy provides the earliest diagnosis
of recurrent MN. At this point, it would be essential to verify
whether or not a subclinical recurrence, that is usually present
when the protocol biopsy is performed, may have consequences
on the graft prognosis. If so, the protocol biopsy may be essential
to obtain a diagnosis before the progression of the disease to a
more severe stage. Several studies have shown that a clinically
silent disease at the time of biopsy typically progresses to overt
proteinuria and NS when followed over time (29, 32). A study
by El-Zoghby et al. reported an increasing level of proteinuria
from 331 mg/d to 1409 mg/d during a 19 months follow up
in 14 patients with recurrent MN. The authors also found that
the earlier diagnosis obtained in patients diagnosed by protocol
biopsies was associated with a significantly lower proteinuria
compared with patients in whom the graft biopsy was performed
on clinical indications (28). In addition, Grupper et al. reported a
persistent histological activity in both untreated patients without
progressive proteinuria, and in rituximab treated patients who
obtained a complete or partial remission (42). These results
confirmed that recurrent MN may be considered a progressive
disease, with a high risk of progression even in the presence of
mild proteinuria (30, 32, 45). This progressive outcome should
not be surprising since MN in a transplant candidate is indicative
of a disease which has led to ESRD.
The behavior of anti-PLA2R antibodies post transplantation
may be variable. In patients with recurrent MN, serial titration of
autoantibodies is relevant to assess the risk of disease progression
and the chances of response to treatment, and may help to
differentiate diagnosis in recipients with a history of primary
MN who develop proteinuria. The persistence or reappearance
of anti-PLA2R after transplantationmay herald amore aggressive
disease with a lower response to immunosuppressive therapy and
a longer time to remission. In patients who obtain immunological
and clinical remission after treatment, reappearance of anti-
PLA2R antibodies may herald the relapse of the disease (39).
However, disappearance of anti-PLA2R shortly after transplant,
due to immunosuppression or unknown factors related to
antigen exposure in the allograft, is not always reassuring.
In some cases this finding corresponds to a lower risk of
recurrence but in others the few circulating autoantibodies can
be trapped in the graft and although undetectable in the serum
may accumulate in the glomeruli and cause recurrence despite
apparent immunological remission (11, 39, 46).
It must be kept in mind that in seronegative patients
with recurrent MN, it is possible that other autoantibodies to
podocyte antigens, like THSD7A or the cytoplasmic antigens,
could be involved, but their role in recurrent MN is still
undefined (18).
The impact of recurrence on renal survival has been evaluated
differently. Some investigators reported no significant difference
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TABLE 2 | Results of treatment of recurrent MN with rituximab.
References Dose of rituximab Number of treated patients Percent CR/PR Proteinuria g/day
Gallon et al. (57) 4 weekly doses (375 mg/m2) 1 NA From 16 to 0.5
El-Zoghby et al. (28) 2 doses (1,000mg) 2-week apart 8 55/30 NA
Sprangerset al. (32) 4 weekly doses (375 mg/m2) or 2 doses (1,000mg) 2-week apart 4 NA From 4 to 1.8
Debiec et al. (58) 2 doses (375 mg/m2 ) 2-week apart 1 NA From 5.1 to 0.4
Spinner et al. (59) Single dose 100–1,000mg (median 200) 20 40/15 NA
Gupta et al. (41) 1–2 doses 375 mg/m2 2-week apart 6 NA From 6 to 0.6
Grupper et al. (42) 2 doses (1,000mg) 2-week apart 17 53/29 NA
CR, complete remission; PR, partial remission.
in patient and graft survival between patients with and without
recurrence (32), while others have shown a progression to
ESRD between 60 and 65% of patients with rMN, after a
mean interval of 4 years from diagnosis (37, 47). Data from
the largest series to date support the negative influence of
recurrent disease on allograft survival. Using the ERA-EDTA
registry database, Pippias et al. assessed death-adjusted graft
survival in 708 patients with primary MN compared with
those in 7,181 patients with autosomal dominant polycystic
kidney disease, in which the native kidney disease cannot
recur. The 5-, 10-, and 15-year adjusted relative risk of
death-adjusted graft failure was, respectively of 1.46 (95%
CI: 1.18–1.82), 1.60 (1.34–1.91), and 1.65 (1.40–1.95). These
negative effects were ascribed to detrimental effects of MN
recurrence (38).
In summary the results of these studies suggest that recurrent
MN has a more insidious course than primary MN, with a
potential histologic progression regardless of the clinical status
that can lead to unexpected negative consequences on graft
function. Surveillance of recurrence in the kidney graft recipients
with biopsy may provide an opportunity to prevent further
allograft dysfunction at an early stage, when the disease may
theoretically be more responsive to therapy (48).
TREATMENT OF RECURRENT MN
Symptomatic treatment of recurrent MN with diuretics, ACE-
inhibitors, ARB, hypolipaemic drugs, and anticoagulants, may
help to attenuate the signs and symptoms related to the NS.
There is evidence however, that these measures fail to prevent the
progression of the disease in the majority of patients (29).
Currently, there are not established guidelines supporting
therapeutical strategies to prevent and treat recurrent MN.
Steroids, calcineurin inhibitors and antiproliferative agents,
which have been used in patients with primary MN do not
have a protective effect in the prevention of recurrence,
and there is no suggestion that modifying traditional post-
transplant immunosuppression may reduce its risk. Sometimes
the post-transplant induction immunosuppression may
obtain a temporary inhibition of anti-PLA2R production but
seronegativity does not exclude deposition of PLA2R in the
glomeruli. The traditional regimens for primary MN are of
little or no benefit in recurrent MN. Calcineurin inhibitors
that may be effective in primary MN (49, 50) do not seem to
improve the clinical course of recurrent MN (29, 37, 47, 51).
Anecdotal cases of response to cyclical therapy with steroids and
cyclophosphamide were reported (27, 52) but cytotoxic agents
may result in potentially dangerous overimmunosuppression in
transplanted patients.
With a better understanding of the pathogenesis of primary
MN, agents acting against B cells constitute a more selective
form of therapy. Rituximab has emerged as a promising
therapeutic option in patients with primary MN in the native
kidney (4, 53–55). It binds specifically to CD20, an antigen
expressed by most human B lymphocytes, resulting in rapid
and sustained depletion of circulating and tissue B cells (56).
The first report of successful rituximab treatment in primary
MN appeared in 2002. Since then, several Authors have
published their positive experience, although still randomized
controlled studies are not available. Overall, complete remission
(CR) occurs in about 15–20% and partial remission (PR) in
35–40% of patients. The clinical response to rituximab has
been described in relation to its effects on anti-PLA2R titers.
Since changes in anti-PLA2R levels (immunologic remission)
precedes proteinuria reduction (clinical remission) by months,
monitoring anti-PLA2R titer may help to earlier understand the
treatment effectiveness as compared with the clinical response
of proteinuria.
Good results with this agent are also reported in recurrent
MN. Gallon et al. first described a case of successful treatment
of recurrent MN with 4 weekly doses of rituximab 375 mg/m2,
which obtained a significant reduction in proteinuria from 16
g/day to 0.5 g/day at 3 years (57). Subsequently, several other
authors have published on the beneficial effects of rituximab in
this setting on case reports or small series (see Table 2). Three
larger series are available in the literature. A study by El-Zoghby
et al. reported on 8 patients with recurrent MN and a mean
proteinuria of 4.4 g/24 h, treated with 2 doses of rituximab,
1,000mg iv each, given 2 weeks apart. After rituximab there
was a prompt and prolonged reduction in CD19 count in all
patients. The count remained below the normal range in the 7
patients tested at 12 months, and in the 4 patients tested at 24
months. Treatment obtained a progressive increase in the percent
of responses over the first 24 months following rituximab, when
a CR or PR was present in 6 out of 7 patients. Among responders,
one patient relapsed and was successfully retreated. Two patients
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developed serious infections within the year following treatment
(1 pneumonia, 1 histoplasmosis). Post treatment biopsies showed
resolution of electron dense immune deposits in 6/7 cases (28).
Gupta et al. treated 6 patients with recurrent MN with 1-2
doses of rituximab (375 mg/m2 two weeks apart). In all patients
proteinuria improved from a median of 6 g/d (range 3.6–19.6)
to 0.6 g/d (range 0.1–2.2) after a median follow up of 5.8 years.
Among the 5 patients with positive anti-PLA2R pretransplant
and at the time of recurrence, titers fell to a median of 4 RU/mL
(41). A recent study from the Mayo Clinic reported the response
to rituximab in a larger series of 17 patients with recurrent MN
and progressive proteinuria, who received rituximab, 2 doses of
1,000mg each given intravenously 2 weeks apart. After therapy,
9/17 patients achieved CR (53%), 5 PR (29%), and 3 (18%)
had no apparent response to therapy. Of the 9 patients who
achieved CR after treatment, all maintained remission for 20–92
months and did not require additional therapy. Among the 5
patients with PR, 2 required retreatment with rituximab after
more than 24 months for increasing proteinuria and both of
them achieved the PR again. Within 2 years after anti-CD20
therapy, 5 out of 17 patients (29%) developed serious infections
requiring hospitalization (3 urosepsis, 1 histoplasmosis, and
1 pneumonia). No patient died. Post treatment biopsies were
obtained in 15/17 patients. In 6 of them (40%), there was a
resolution of the histologic findings (5 with CR and 1 with PR),
but in 9 out of 15, immunofluorescence and electron microscopy
showed persistence of active MN (4 with CR, 3 with PR and 2
non-responders) (42).
FIGURE 1 | Antibody-guided diagnosis and treatment algorithm for recurrent MN. RAS-I Renin- angiotensin system inhibitors, PLA2R anti-phospholipase A2 receptor,
THSD7A anti- thrombospondin 1 type 1 domain containing 7A. Question marks on optional points.
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Currently, there are not data on preemtive use of rituximab.
Rituximab is generally considered effective, and more
tolerated as compared to alkylating agents. Another advantage
with rituximab is the unnecessary modification of the anti-
rejection therapy. However, treatment may complicate with
infections in transplanted patients receiving 2–3 additional
immunosuppressants. Therefore, it has been suggested that in
recipients with higher risk of infections such as older recipients,
the dose of anti-CD20may be reduced by half (48, 60). Treatment
rapidly decreases anti-PLA2R. B-cell depletion lasts longer in
transplanted patients than in native MN (28), but it is usually
necessary to wait more than one year to achieve clinical remission
(28, 55, 61). The rate of response to treatment resulted to be
higher in recurrent MN than in native MN. This may be due
to the earlier diagnosis and treatment of the disease in many
patients, and to the additional beneficial effects of the post-
transplant immunosuppression (28). Serological monitoring
for anti-PLA2R levels may represent the earlier biomarker
of immunological response. The change in anti-PLA2R titer
precedes the decline of proteinuria. Therefore, serial titration of
the antibody can be used to predict response to therapy as well as
the possibility of relapse (28).
The optimal dose of rituximab for recurrent MN is still
unknown. Usual dose of rituximab in native MN consists of 375
mg/m2 intravenously once weekly for 4 weeks or the alternative
protocol of 2 doses of 1 g each intravenously 2 weeks apart. The
regimen can be repeated after 6 months if B cells are above 15/µL
or elevated anti-PLA2R levels persist. So far the literature has
not provided a clear indication on the most effective regimen. It
can only be said that, unlike primary MN in the native kidney,
the progressive course of recurrent MN requires treatment at the
earliest stage rather than an initial period of observation. Infact,
in primary MN the amount of proteinuria relates to prognosis
(49) and spontaneous remission of NS may occur in about 1/3
of patients (62). In contrast, recurrent MN appears to have a
much higher chance of progressing even when only minimal
proteinuria is present, and a high rate of success is reported
starting treatment when proteinuria is approaching one gram
per day (29). These observations justify an early treatment of
recurrent MN in allografts.
In summary, although treatment of recurrent MN is still
far from satisfactory, some measures seem to be helpful.
Rituximab is currently considered the first line therapy but
prospective trials in this setting are needed to confirm the
available data. In patients heavily immunosuppressed caution is
recommended in order to avoid severe and even life-threatening
infections. The ideal dose is another important aspect to
be evaluated.
Among transplanted patients who do not respond to
rituximab, cytotoxic agents such as cyclophosphamide may be
cautiously used. If such a therapy is considered, antimetabolic
agents such as mycophenolate mofetil or azathioprine should
be discontinued and patients should be followed up closely for
bone marrow suppression, infection, and malignancy. There are
no rigorous studies that have examined the effects of cytotoxic
agents in recurrent MN. Finally, a successful use of a proteasome
inhibitor (bortezomib) has been reported in recurrent MN with
persistent proteinuria refractory to rituximab (63).
CONCLUSION
Due to the overall longer survival of transplanted kidneys,
recurrency of native diseases has become an increasing cause of
allograft failure (33). In recurrent MN, persistent NS can cause
10% of graft loss within 4.2 ± 2.7 years after transplantation
(28). There is evidence in the literature that an approach
focused on early diagnosis and prompt therapy can improve
graft survival. In this setting the allograft biopsy and the
titration of anti-PLA2R autoantibodies are the main diagnostic
and prognostic tools. Evaluation of anti-PLA2R antibodies
before surgery may predict the risk of recurrence of primary
MN: in patients with persistently high anti-PLA2R levels
preemptive treatment with anti-CD20 could hypothetically be
effective in preventing recurrence. However, data on this subject
are lacking.
The protocol biopsy remains the gold standard for earlier
diagnosis of recurrent MN, prior to its clinical presentation, at
a time point where specific intervention may be more effective.
In transplanted patients with underlying MN, the subsequent
evaluation of anti-PLA2R antibodies level provides information
about the immunological activity and outcome of the disease
and enables clinicians to adjust the immunosuppressive therapy
to the patient’s needs. Thus, in biopsy proven recurrent
MN, the immunological activity (anti-PLA2R levels) and the
clinical activity (proteinuria degree) of the disease should be
followed closely. Regardless of PLA2R levels in patients with
proteinuria reaching 1 g/day, therapy should be considered. Data
regarding rituximab treatment, although still limited, predict
favorable results in the treatment of recurrent MN. Prospective
randomized trials are needed to confirm the reported results.
In case of poor response or intolerance to rituximab, the
cyclical therapy with steroids and cytotoxic agents or with
bortezomibmay be attempted (see Figure 1). Serial measurement
of antibody levels during treatment may be useful to predict
responsiveness to therapy and thereafter may be useful to predict
relapse. We report our clinical practice algorithm in figure 1
(see Figure 1).
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